Physician profile
Abdallah Kernaf
NPI 1679861611
$1,997.01
in general payments reported to CMS, 2019-2025
29 companies · $83.36 in 2025
The $83.36 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $125 · 2021: $312 · 2022: $209 · 2023: $153 · 2024: $766 · 2025: $83.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $647.24 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $302.82 | 2022-2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $241.02 | 2022-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.58 | 2019-2025 | Ofev |
| Edwards Lifesciences Corporation | $93.83 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $61.77 | 2023 | Uptravi |
| Janssen Pharmaceuticals, INC | $58.72 | 2019-2020 | |
| Genentech USA, INC. | $51.03 | 2019 | |
| La Jolla Pharmaceutical Company | $41.88 | 2022 | |
| Merck Sharp & Dohme LLC | $36.69 | 2024-2025 | Zerbaxa |
| Ambu INC. | $30.87 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $30.19 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $28.53 | 2022 | |
| Ethicon INC. | $27.51 | 2024 | Monarch Platform |
| Pulmonx Corporation | $23.79 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $22.49 | 2024 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $22.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.50 | 2024 | Dupixent |
| Csl Behring | $19.86 | 2021 | |
| Circassia INC. | $19.72 | 2019 | |
| Amgen INC. | $15.62 | 2023 | Tavneos |
| Allergan, INC. | $14.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2019 | |
| Biogen, INC. | $13.16 | 2022 | |
| Covidien LP | $12.94 | 2019 | |
| Insmed, INC. | $12.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.41 | 2019 | |
| Melinta Therapeutics, LLC | $11.27 | 2019 | |
| Ge Healthcare | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Kernaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.